AstraZeneca’s Imfinzi/Treme Combo Fails To Match Leaders In First-Line Lung Cancer
Too Little, Too Late In Crowded Market
The immunotherapy drugs fall short of the standard set by Keytruda, but could gain some traction in non-squamous patient group.
You may also be interested in...
Libtayo looks to have surpassed all competitors but Merck’s Keytruda in first line NSCLC, but the unique ‘all-comers’ trial design of EMPOWER-Lung-3 complicates the picture.
Adding oleclumab and monalizumab to the PD-L1 inhibitor improved PFS, while another study showed improved real-world outcomes.
After five years of failure in NSCLC trials, AstraZeneca’s immunotherapy combo shows survival benefits in POSEIDON.